Per-6-substituted beta-cyclodextrin libraries inhibit formation of beta-amyloid-peptide (A beta)-derived, soluble oligomers
- PMID: 12212793
- DOI: 10.1007/s12031-002-0010-x
Per-6-substituted beta-cyclodextrin libraries inhibit formation of beta-amyloid-peptide (A beta)-derived, soluble oligomers
Abstract
Alzheimer's disease is the most common cause of dementia in older individuals with compelling evidence favoring neuron dysfunction and death triggered by assembled forms of A beta(1-42). While large neurotoxic amyloid fibrils have been known for years, recent studies show that soluble protofibril and A beta(1-42)-derived diffusible ligands (ADDLs) may also be involved in neurotoxicity. In the present work, dot-blot immunoassays discriminating ADDLs from monomers were used to screen libraries of per-substituted beta-cyclodextrin (beta-CD) derivatives for inhibition of ADDLs formation. Libraries were prepared from per-6-iodo-beta-CD by treatment with various amine nucleophiles. The most active library tested (containing >2000 derivatives) was derived from imidazole, N, N-dimethylethylenediamine and furfurylamine, which at 10 microM total library, inhibited ADDLs formation (10 nM A beta(1-42)) over a period of 4 hours. The latter was confirmed by a western blot assay showing decreased amounts of the initially formed A beta(1-42) tetramer. These preliminary experiments suggest that derivatized forms of beta-CD can interfere with the oligomerization process of A beta(1-42).
Similar articles
-
Femtomole immunodetection of synthetic and endogenous amyloid-beta oligomers and its application to Alzheimer's disease drug candidate screening.J Mol Neurosci. 2003;20(3):305-13. doi: 10.1385/JMN:20:3:305. J Mol Neurosci. 2003. PMID: 14501013
-
Per-6-substituted-per-6-deoxy beta-cyclodextrins inhibit the formation of beta-amyloid peptide derived soluble oligomers.J Med Chem. 2004 Jun 17;47(13):3329-33. doi: 10.1021/jm034224e. J Med Chem. 2004. PMID: 15189029
-
NMR and CD studies on the interaction of Alzheimer beta-amyloid peptide (12-28) with beta-cyclodextrin.Biochem Biophys Res Commun. 2002 Oct 4;297(4):1011-15. doi: 10.1016/s0006-291x(02)02337-9. Biochem Biophys Res Commun. 2002. PMID: 12359256
-
Discovery of ADDL--targeting small molecule drugs for Alzheimer's disease.Curr Alzheimer Res. 2007 Dec;4(5):562-7. doi: 10.2174/156720507783018271. Curr Alzheimer Res. 2007. PMID: 18220523 Review.
-
Low-n oligomers as therapeutic targets of Alzheimer's disease.J Neurochem. 2011 Apr;117(1):19-28. doi: 10.1111/j.1471-4159.2011.07187.x. Epub 2011 Feb 9. J Neurochem. 2011. PMID: 21244429 Review.
Cited by
-
Dye-binding assays for evaluation of the effects of small molecule inhibitors on amyloid (aβ) self-assembly.ACS Chem Neurosci. 2012 Nov 21;3(11):807-19. doi: 10.1021/cn300076x. Epub 2012 Aug 6. ACS Chem Neurosci. 2012. PMID: 23173064 Free PMC article. Review.
-
Alzheimer's-associated Abeta oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal.Toxicol Appl Pharmacol. 2009 Oct 15;240(2):189-97. doi: 10.1016/j.taap.2009.07.018. Epub 2009 Jul 23. Toxicol Appl Pharmacol. 2009. PMID: 19631677 Free PMC article.
-
Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases.Molecules. 2016 Dec 20;21(12):1748. doi: 10.3390/molecules21121748. Molecules. 2016. PMID: 27999408 Free PMC article. Review.
-
Tumor necrosis factor death receptor signaling cascade is required for amyloid-beta protein-induced neuron death.J Neurosci. 2004 Feb 18;24(7):1760-71. doi: 10.1523/JNEUROSCI.4580-03.2004. J Neurosci. 2004. PMID: 14973251 Free PMC article.
-
Femtomole immunodetection of synthetic and endogenous amyloid-beta oligomers and its application to Alzheimer's disease drug candidate screening.J Mol Neurosci. 2003;20(3):305-13. doi: 10.1385/JMN:20:3:305. J Mol Neurosci. 2003. PMID: 14501013
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical